Médica y casi pediatra. Ahora haciendo camino en la industria farmacéutica. Mamá de Iñaki y Nico y casada con un genio. De la tierra del mate y amante del café.
Reflecting back on #ASCO25 I keep thinking that in oncology we have rare opportunities to celebrate and thankfully DeLLphi-304 was one of them! So grateful to this wonderful team of researchers and collaborators involved from phase 1 of Tarlatamab up to registration
#some#LCSM
Original Article: Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy (DeLLphi-304 phase 3 trial) https://t.co/mDL754T54Z
#ASCO25 | @ASCO
DLL3 is a protein expressed on the cell surface of small cell lung cancer (#SCLC) tumors and represents a promising therapeutic target for SCLC. At @Amgen, we’re investigating T-cell engagers as a next-generation immunotherapy to target DLL3.
Amgen announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline that highlights our progress in advancing all angles of care for patients with high unmet need.
➡️ Press release: https://t.co/AaeAeZsq7e
$AMGN #ASCO23